Lupus & antiphospholipid syndrome
Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data
Authors' conclusion
This analysis showed significant reductions in OCS dose and use in patients with SLE who persisted with belimumab, providing more real-world evidence for belimumab's steroid-sparing effect.
Study context
- Population
- Adults with SLE in a US rheumatology network who initiated belimumab between 1 January 2012 and 30 June 2021, with >180 days pre- and >360 days post-initiation dataFull analysis set (FAS)
- Participants
- 608 adults
- Exposure
- Oral corticosteroid (OCS) use pre-belimumab initiation vs post-initiation
- Outcome
- Changes in OCS use in patients with OCS use in P1 who persisted with belimumab
Methodological detailspre- vs post-belimumab initiation, real-world data, PIONEER-Rheumatology database
- Pre- vs post-belimumab initiation
- Real-world data
- PIONEER-Rheumatology database
Main finding
As reported in the abstract
Proportion receiving OCS, among patients receiving OCS in P1
Observational data: associations, not effects.
Further findings
Mean total OCS dose/patient, mean daily OCS dose for days supplied, proportions with OCS ≤5 mg/day and ≤7.5 mg/day
- Significant reductions from P1 in P2 and P3
Mean total OCS days supplied/patient
- Significant reduction from P1 in P3 only
OCS use in P1
- FAS patients receiving OCS in P1
- 56.3%
- Patients persisting with belimumab for 360 days receiving OCS in P1
- 54.5%
Original publication
Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Sci Med. Published 22 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →